Rhumbline Advisers lifted its stake in Inogen, Inc (NASDAQ:INGN) by 4.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 33,512 shares of the medical technology company’s stock after acquiring an additional 1,390 shares during the quarter. Rhumbline Advisers owned approximately 0.16% of Inogen worth $3,187,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Teachers Advisors LLC increased its position in Inogen by 2.8% during the first quarter. Teachers Advisors LLC now owns 27,790 shares of the medical technology company’s stock worth $2,155,000 after buying an additional 749 shares during the last quarter. Aperio Group LLC acquired a new position in Inogen during the second quarter worth $854,000. Municipal Employees Retirement System of Michigan increased its position in Inogen by 4.4% during the second quarter. Municipal Employees Retirement System of Michigan now owns 3,820 shares of the medical technology company’s stock worth $365,000 after buying an additional 160 shares during the last quarter. Great West Life Assurance Co. Can increased its position in Inogen by 1.8% during the second quarter. Great West Life Assurance Co. Can now owns 49,358 shares of the medical technology company’s stock worth $4,704,000 after buying an additional 860 shares during the last quarter. Finally, Texas Permanent School Fund increased its position in Inogen by 1.4% during the second quarter. Texas Permanent School Fund now owns 11,871 shares of the medical technology company’s stock worth $1,133,000 after buying an additional 159 shares during the last quarter.
INGN has been the topic of several analyst reports. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 target price on the stock in a research report on Thursday, November 9th. Needham & Company LLC reissued a “buy” rating and set a $108.00 target price on shares of Inogen in a research report on Friday, September 1st. BidaskClub downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research report on Tuesday. Piper Jaffray Companies reissued a “hold” rating and set a $90.00 target price on shares of Inogen in a research report on Tuesday, September 12th. Finally, Leerink Swann reissued an “outperform” rating and set a $120.00 target price (up from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. Four research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $103.14.
In other news, EVP Alison Bauerlein sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $94.93, for a total value of $1,423,950.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Byron Myers sold 35,000 shares of the firm’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $116.77, for a total value of $4,086,950.00. Following the completion of the sale, the executive vice president now directly owns 48,600 shares in the company, valued at $5,675,022. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 88,000 shares of company stock worth $9,349,730. 5.31% of the stock is currently owned by company insiders.
Shares of Inogen, Inc (NASDAQ:INGN) opened at $118.21 on Friday. The stock has a market capitalization of $2,460.00, a PE ratio of 95.47, a PEG ratio of 4.93 and a beta of 1.13. Inogen, Inc has a 1 year low of $62.69 and a 1 year high of $130.05.
Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.04. The company had revenue of $69.00 million for the quarter, compared to the consensus estimate of $63.55 million. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The firm’s revenue was up 26.8% compared to the same quarter last year. During the same period last year, the business posted $0.25 earnings per share. equities research analysts predict that Inogen, Inc will post 1.19 EPS for the current fiscal year.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.